You are here

Our science / Clinical Trials / Find a Trial / NCT01789905

Tygacil Drug Use Investigation

Back to Search Print Save as PDF Bookmark Trial

NCT01789905

Last updated on December 25, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Intra-Abdominal Infections, Infectious Skin Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All patients who are prescribed tigecycline (Tygacil).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subject who have been prescribed tigecycline (Tygacil).

NCT01789905
Pfizer
Completed
Tygacil Drug Use Investigation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
NCT03801928
All Genders
18+
Years
Columbia, Maryland
Meningococcal B Disease
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
NCT02534935
All Genders
1+
Years
Multiple Sites
Common Cold, Upper Respiratory Tract Infections
Acute Cough Study In Children
NCT01257542
All Genders
6+
Years
Multiple Sites
Anaerobic Infection, Infectious Enterocolitis, Amebic Dysentery
Anaemetro I.V. Infusion 500mg Drug Use Investigation
NCT03491228
All Genders
Tygacil Drug Use Investigation
Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-drug Resistance.)
To retrospectively collect the effectiveness and safety information of tigecycline related to their appropriate use in daily practice.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
The patients whom an investigator involving B1811187 prescribes the tigecycline (Tygacil).
  • Intra-Abdominal Infections
  • Skin Disease, Infectious
Drug: Tigecycline (Tygacil)
Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Other Name: Tygacil, Tigecycline
Tigecycline (Tygacil)
Subjects who are treated with tigecycline
Intervention: Drug: Tigecycline (Tygacil)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
116
June 16, 2017
June 16, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients who are prescribed tigecycline (Tygacil).

Exclusion Criteria:

  • Subject who have been prescribed tigecycline (Tygacil).
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01789905
B1811187
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now